Stocks analysis

ABBV vs AMD Stock Comparison

Scores Breakdown

Metric ABBV AMD
📈 Growth 15/30 28/30
💰 Profitability 16/20 16/20
🏦 Financial Health 12/20 18/20
💵 Valuation 12/20 15/20
⚠️ Risk (lower is better) 6/10 7/10
Overall Score 59/100 80/100

Side-by-Side Summaries

ABBV Analysis AMD Analysis

📈 Growth & Financial Trajectory

8 quarters show a largely rising topline: 2024Q1 to 2026Q1 Revenues rise from about $12.31B to $15.00B (+≈22%). Net income attributable to parent falls from ~$1.29B to ~$0.70B, though peaks around ~$1.86B in 2025Q2–Q3, with 2025Q4 at ~$1.82B. The trend is mixed: topline strength persists, but bottom-line profitability weakens into 2026Q1.

💰 Margins & Cash Flow

Gross margins remain high, broadly ~70–79%, reflecting a durable product mix. Operating leverage remains healthy as volumes expand. Net cash flow from operating activities stays robust, typically around $5.1B–$5.3B per quarter; investing activity is negative (capex/activity), and financing flows cause periodic swings.

🛡️ Balance Sheet & Liquidity

Total assets hover near the mid-to-upper hundreds of billions with liabilities that verge on or exceed assets in some periods, and equity attributable to the parent is often negative (reflecting buybacks). The firm generates solid operating cash flow that supports liquidity despite leverage. Long-term debt runs in the mid-$60B range in recent periods, with current liabilities ~$39–$44B.

⚠️ Key Drivers & Risks

  • Drivers: Robust pharma demand and a durable high-margin mix; ongoing pipeline progress.
  • Risks: Patent/regulatory pressures; elevated leverage and sensitivity to interest rates; potential valuation volatility.

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from roughly $7.44B to about $10.25B, a sustained upshift with a brief mid-period pause. Net Income climbed from about $0.264B to $1.383B, with quarterly oscillations but a clear uptrend (peaks in 2025 Q4 and 2026 Q1).

💰 Margins & Cash Flow

Gross margins held near 50-54%, with quarterly gross profit around $3.0-5.6B on rising revenues. Operating margins stayed in the mid-teens (~14-17%), reflecting improving operating leverage as volumes grow. Cash flow from operations was positive in each period (approx. $1.0-3.0B per quarter), with investing cash outflows offset by financing activity and net cash flow turning positive in several quarters.

🛡️ Balance Sheet & Liquidity

Equity attributable to parent ranges around $58-64B with total assets near $69-79B. Current assets about $19-28B and current liabilities around $7-10B yield a healthy liquidity cushion. Debt levels remain modest relative to equity, supporting resilience.

⚠️ Key Drivers & Risks

  • Drivers: AI/Data Center GPU demand; AMD product cadence and process technology advantages.
  • Risks: Semiconductor cyclicality and valuation sensitivity to growth trajectories; competitive pressure in a consolidating GPU/CPU market.